Strategic partnerships FYR Bio leverages collaborations with Mayo Clinic, Medicover, and academic researchers to advance EV biomarkers, presenting opportunities for co-development deals, sponsored research, and service partnerships with large healthcare networks and pharma companies.

Expansion momentum Recent funding and expansion into oncology and neuroscience indicate a growth trajectory and need for scalable services, paving the way for multi-therapy biomarker programs, contract research, and platform licensing with biotech and pharma customers.

AI powered insights FYR’s EVO platform combines extracellular vesicle enrichment with AI-driven multiomics, offering a compelling value proposition for diagnostic tool development, companion diagnostics, and data-driven patient stratification services for drug developers.

Executive alignment New COO appointment signals organizational scaling and improved operations, creating opportunities to position FYR for enterprise-grade collaborations, contract manufacturing or CRO partnerships, and larger-scale commercial pilot programs.

Target markets With a footprint spanning oncology and neuroscience and a history of diagnostics collaborations, sales opportunities exist with pharma/biotech companies seeking biomarker discovery, clinical trial enrichment, and non-invasive testing solutions leveraging blood-based EVomics.